newsfilter
← Latest News
GlobeNewswire·

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO Trial Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start $37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operatio